Werewolf Therapeutics, Inc. (HOWL)
US — Healthcare Sector
Automate Your Wheel Strategy on HOWL
With Tiblio's Option Bot, you can configure your own wheel strategy including HOWL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HOWL
- Rev/Share 0.0255
- Book/Share 1.2784
- PB 0.9465
- Debt/Equity 0.182
- CurrentRatio 8.0947
- ROIC -0.5819
- MktCap 54297056.0
- FreeCF/Share -1.3381
- PFCF -0.9052
- PE -0.7491
- Debt/Assets 0.0973
- DivYield 0
- ROE -0.8937
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
HOWL
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
HOWL
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year –
Read More
About Werewolf Therapeutics, Inc. (HOWL)
- IPO Date 2021-04-30
- Website https://werewolftx.com
- Industry Biotechnology
- CEO Dr. Daniel J. Hicklin Ph.D.
- Employees 46
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.